Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.

Trine-Lise LarsenHerish GarresoriJorunn BrekkeTone EndenHege FrøenEva Marie JacobsenPetter Quist-PaulsenAlina Carmen PorojnicuAnne Hansen ReeDag TorfossElin Osvik VelleHilde Skuterud WikWaleed GhanimaPer Morten Sandset Anders Erik Astrup Dahm

Published in: Journal of thrombosis and haemostasis : JTH (2022)

Dose reduction of apixaban to 2.5 mg twice daily seems safe after 6 months of full-dose treatment. After 12 months the incidence rate of recurrent VTE and major bleeding remained low.

Keyphrases

venous thromboembolism
low dose
direct oral anticoagulants
atrial fibrillation
risk factors
high dose
physical activity